Table 1.
Demographic and clinical characteristics
| Patients (n = 19) | Controls (n = 19) | p-value | |
|---|---|---|---|
| Age at baseline (years) | 50.2 (8.6) | 49.3 (9.0) | 0.76 |
| Education | 0.66 | ||
| High School | 2 | 3 | |
| College | 8 | 8 | |
| Undergraduate Degree | 5 | 2 | |
| Graduate Degree | 4 | 6 | |
| Menopausal status at baseline | 0.82 | ||
| Menstruating | 8 | 9 | |
| Perimenopausal | 4 | 2 | |
| Postmenopausal | 7 | 8 | |
| Cancer stage | |||
| I | 3 | – | |
| II | 13 | – | |
| III | 3 | – | |
| Chemotherapy regimen | |||
| FEC-D (six cycles)1 | 12 | – | |
| FEC-D (five cycles) | 1 | ||
| CD (four cycles) | 4 | – | |
| CDOX (four cycles)2 | 2 | – | |
| Type of surgery | |||
| Modified Radical MX | 7 | – | |
| Simple MX | 1 | – | |
| Segmental MX | 3 | – | |
| Lumpectomy | 8 | – | |
| Time between (days) | |||
| Surgery to T1 MRI | 49.9 (15.2) | – | |
| T1 MRI to chemo | 6.2 (4.9) | – | |
| End chemo to T2 MRI | 32.0 (15.3) | – | |
| T1 MRI to T2 MRI | 128.8 (23.0) | 127.0 (25.0) | 0.81 |
| T2 MRI to T3 MRI | 406.16 (70.3) | 449.7 (106.9) | 0.15 |
Mean (SD) or count values are shown. Units are arbitrary unless otherwise specified. FEC-D: fluorouracil + epirubicin + cyclophosphamide + docetaxel; CD: cyclophosphamide + docetaxel; CDOX: cyclophosphamide + doxorubicin; MX: mastectomy. 1Two cases with epirubicin and one case with bevacizumab; 2one case with paclitaxel.